Epix, Nanotherapeutics, Oscient deal

Nanotherapeutics acquired Oscient's Ramoplanin for $500,000 in bankruptcy proceedings. The macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis is entering Phase III trials to treat Clostridium difficile-associated diseases. Nanotherapeutics also acquired Epix's PRX-03140, plus two preclinical small molecules at auction for $32,000. PRX-03140 is a serotonin (5-HT4) receptor agonist in Phase II testing to treat Alzheimer's disease. Nanotherapeutics plans to continue development of the compounds, with the goal of out-licensing them at some point in the future. ...